Monday, 21 December 2009 - 08:40
Sanofi-Aventis Discontinues Eplivanserin For Insomnia
PARIS -(Dow Jones)- French drug maker Sanofi-Aventis S.A. (SNY) Monday said it's discontinuing the development of two drugs, eplivanserin for insomnia and idrabiotaparinux for atrial fibrillation.
In a statement updating the situation in its research and development pipeline, which the company has streamlined since the arrival of Chief Executive Chris Viehbacher, Sanofi-Aventis said it was withdrawing its application with U.S. and European authorities for the eplivanserin insomnia treatment after a letter from the U.S. Food and Drug Administration in September.
As for the idrabiotaparinux heart treatment, Sanofi cited a lack of "significant improvement" for patients from the compound as the reason for discontinuing its development.
Sanofi has pared down its pipeline of drug development under the leadership of Viehbacher, who has stressed partnerships and acquisitions for obtaining new drugs.
Sanofi Monday also said that the FDA has granted fast track processing to its prostate cancer treatment cabazitaxel and that the European medicines Agency issued a positive opinion and a recommendation to grant marketing authorization for its DuoPlavin coronary treatment.
-By Mimosa Spencer and Elena Berton, Dow Jones Newswires; +33 140 17 17 73; email@example.com
(END) Dow Jones Newswires
December 21, 2009 01:40 ET (06:40 GMT)
Copyright (c) 2009 Dow Jones & Company, Inc.